ORIC
ORIC Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.90
+1.22%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.5x
Market Cap
$1.34B
MomentumView details →
1D Return
+1.22%
YTD Return
+56.41%
RSI (14)
48.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.5x
Market Cap
$1.34B
RSI (14)
48.2
MomentumView details →
1D Return
+1.22%
YTD Return
+56.41%
SummaryUpdated Jun 1, 2026
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in South San Francisco, California. The company went public in April 2020 and focuses on discovering and developing precision cancer therapies that target specific resistance mechanisms in oncology. ORIC operates as a research-driven organization that aims to overcome the challenges patients face when their cancers become resistant to existing treatments, including both chemotherapy and newer immunotherapy approaches.
Similar companies
Latest newsMore news →
ORIC Pharmaceuticals granted 125,400 non-qualified stock options and 20,550 restricted stock units to five new non-executive employees on August 3, 2026, as inducement grants under Nasdaq Listing Rule 5635(c)(4).28d agoORIC Pharmaceuticals initiated the Himalayas-1 global Phase 3 trial of rinzimetostat in combination with darolutamide for mCRPC patients previously treated with abiraterone.52d ago